Product Information
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB is a generic product labeled by Accord Healthcare Inc., priced at $0.1751 per EA under NDC 16729036615. Its NADAC has been published 292 times since Oct 21, 2020.
FDA first approved this application on Feb 7, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDEStrength
12.5; 20 mg/1; mg/1
Manufacturer
Accord Healthcare Inc.NDC
16729036615
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA209281FDA Approved
2/7/2019
TE Code
AB
On Market Since
9/21/2020
Pharmacological Classes
Price Statistics
The NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has been published 292 times since Oct 21, 2020, and over the history we have for it it has declined 63.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1751 per EA |
|---|---|
| All-time high | $0.4784 (Nov 11, 2020) |
| All-time low | $0.1502 (Nov 20, 2024) |
| 52-week high | $0.1751 |
| 52-week low | $0.1669 |
| Median price | $0.2043 |
| Average price | $0.2169 |
| Largest weekly change | -40.2% (Nov 18, 2020) |
| Weeks tracked | 292 |
| Tracking since | Oct 21, 2020 |
1W
N/A
1M
N/A
3M
N/A
6M
+3.5%
1Y
+0.5%
3Y
-14.3%
5Y
-35.3%
All
-63.4%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Accord Healthcare Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB, manufactured by Accord Healthcare Inc., is $0.1751 per EA (NDC 16729036615), effective May 20, 2026.
How has the price of OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has declined 63.4%. It has been tracked across 292 weekly CMS publications since Oct 21, 2020.
What are the highest and lowest recorded NADAC prices for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
Since Oct 21, 2020, the NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has ranged from a low of $0.1502 (Nov 20, 2024) to a high of $0.4784 (Nov 11, 2020), with a median of $0.2043 per EA.
Are there cheaper alternatives to OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB, is $0.1650 per EA — about 6% below OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB.
Who manufactures OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB (NDC 16729036615) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.